New In Store

Lorem ipsum dolor sit amet, consectetur adip is cing elit, sed do eiusmod tempor

Categories :

Let’s connect

icon

12+ Years of Excellence in Anabolic Steroids

Earn Points with Every Purchase

For every $1 you spend, you’ll gain 1 Canadian Made Labs Reward Point. Don’t wait — register today and begin enjoying seamless savings!

Rewards Program

Fast, Free Shipping on All Orders $399+

Shop Now

Refer Your Friends & Get 15% Off

Referral Program

The Top Canadian Source For Anabolic Steroids Since 2012

Free Shipping on Orders $400+

Search

No products in the cart.
No products in the cart.
Image Alt

Shop

  /    /  Peptides  /  Bioglutide (10mg)

Bioglutide (10mg)

$220.00

Bioglutide (NA-931) is an investigational oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors, under research for obesity and type 2 diabetes. For laboratory use only.

SKU: dynamic-bioglutide-10mg Category:

Description

Dosage (Male)

1–12 mg once weekly (titrated)

Dosage (Female)

1–12 mg once weekly (titrated)

Frequency

Once per week

Dosage Type

Subcutaneous Injection

Active Half-Life

6–7 days

Post-Cycle PCT

N/A

What is
Bioglutide?

Bioglutide (NA-931) is an investigational quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors simultaneously. This multi-pathway approach regulates appetite, enhances insulin sensitivity, boosts energy expenditure, and supports lean mass preservation during weight loss. Early clinical data show significant reductions in body weight, blood sugar, and visceral fat, with a favorable tolerability profile compared to current injectable GLP-1 therapies. Administered as a once-weekly subcutaneous injection, Bioglutide is under active investigation for obesity, type 2 diabetes, and related metabolic conditions. It is not FDA-approved and is intended for laboratory research only.

The Benefits of
Bioglutide

Bioglutide is a next-generation investigational compound designed to support substantial weight loss and broad metabolic improvement. As a quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 pathways, it addresses appetite regulation, glucose control, energy expenditure, and muscle preservation within a single compound. Phase 1 and early Phase 2 data suggest 10–14% body weight reduction over 12–13 weeks, with a cleaner gastrointestinal side effect profile than existing injectable options. The addition of IGF-1 receptor activity sets Bioglutide apart from semaglutide and tirzepatide, introducing the possibility of preserving lean muscle mass during aggressive caloric deficit. For research purposes, it represents one of the most mechanistically comprehensive metabolic compounds currently in development.

Need Help With the 
Correct Peptide Mix?

Our peptide mixing calculator takes the guesswork out of dosing, giving you an exact, easy-to-follow guide based on your vial, syringe, and target dosage. Whether you’re new to peptides or simply want to double-check your math, we’ve made it simple and straightforward.

Just enter your total syringe volume, the amount of peptide in your vial, how much water you’re adding, and your desired peptide dose. The calculator will do the rest — making sure you get accurate measurements for safe, consistent use every time.

For A MCG Dose, Draw Up To Tick Mark .

These ranges are general, research-use suggestions to help you prepare your peptides. This calculator and recommended doses are not medical advice. Start low, assess tolerance, and adjust cautiously.

Revitalizing Health and Longevity

Canadian Made Labs peptide supplements – transform your body and elevate your health. These compounds are made from the highest quality ingredients that promote overall wellness, improves performance, and contributes to a longer, more vibrant life. Our peptides provide a comprehensive approach to health and fitness, boosting muscle growth, speeding recovery, and enhancing mental sharpness.

The Premier Source for Elite Peptides

Canadian Made Labs is your go-to spot for peptides made with the purest and finest ingredients as we strive and maintain our reputation for delivering the highest quality products in all of North America. Experience the difference when it comes to our dedication to excellence, providing the best customer service possible, and our products are supported by rigorous quality controls ensuring pharmaceutical-grade quality.

Side Effects & Considerations for
Bioglutide

Bioglutide may cause gastrointestinal symptoms including nausea, vomiting, diarrhea, or constipation, particularly during dose escalation. Appetite suppression may lead to inadequate caloric intake. Other potential effects include fatigue, abdominal discomfort, and injection site irritation. Hypoglycemia is possible when used alongside other glucose-lowering agents. Rapid weight loss may increase gallstone risk. Individuals with a history of pancreatitis or thyroid disorders should exercise additional caution. Long-term safety and efficacy data remain under investigation. For research use only; not for use in humans outside of supervised clinical trial settings.

Dosage (Male)

1–12 mg once weekly (titrated)

Dosage (Female)

1–12 mg once weekly (titrated)

Frequency

Once per week

Dosage Type

Subcutaneous Injection

Active Half-Life

6–7 days

Post-Cycle PCT

N/A

Dosage Guidelines for
Bioglutide

Bioglutide is administered via subcutaneous injection once weekly, typically in the abdomen or thigh. Research protocols begin at 1 mg weekly, with gradual titration over several weeks up to 12 mg based on tolerance and observed response. Slow titration reduces the likelihood of gastrointestinal side effects during escalation. Injections may be taken with or without food and should be administered on the same day each week to maintain consistent serum levels. If a dose is missed, administer within 4 days; otherwise skip and resume the regular schedule. This compound is investigational and for laboratory research use only.

Reviews

There are no reviews yet.

Be the first to review “Bioglutide (10mg)”

Your email address will not be published. Required fields are marked *